Preclinical in-vitro studies have shown that the combination of Vorinostat with Dasatinib leads to the death of CML primary cells and can also attenuate the levels of expression of E255K and T315I-BCR-ABL mutants [10]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.